Abstract:Purpose/Objective(s) Efficacy of immune checkpoint inhibitors (ICI) in curative head and neck squamous cell carcinoma (HNSCC) may be hampered by therapeutic ablation of tumor-draining lymphatics with standard chemoradiation (CRT). Recent emergence of neoadjuvant immunotherapy in HNSCC highlights the need for biomarkers to optimize anti-tumor immunity while eliminating locoregional microscopic disease. An elevated neutrophil-to-lymphocyte ratio (NLR) may reflect an unfavorable balance between pro-tumor inflammation and anti-tumor immunity and is associated with poor immunotherapy outcomes, yet its role as a biomarker of neoadjuvant HNSCC immunotherapy is unknown. We studied the association between NLR dynamics and prognosis in HNSCC patients treated with neoadjuvant immuno-chemotherapy followed by dose and volume response-stratified CRT. Materials/Methods 106 (71 HPV positive and 35 HPV negative) locoregionally advanced HNSCC patients prospectively enrolled in two clinical trials (NCT03107182; NCT039449150) were treated with neoadjuvant nivolumab and chemotherapy followed by dose and volume response-stratified treatment with reduced or standard CRT (including elimination of elective nodal radiation). NLRs for each patient were calculated at baseline, after neoadjuvant therapy, and 1, 3, 6, 9, and 12 months after treatment completion. NLRs at baseline and after neoadjuvant therapy were divided into quartiles, with high NLRs being the highest quartile (>3.66 and >5.63, respectively). NLR differences between reduced and standard CRT groups were analyzed by Wilcoxon ranked sum test. Overall survival (OS) and progression free survival (PFS) were analyzed by Kaplan-Meier and Cox regression methods. Results Among HPV positive patients, 37% were Stage II/III; among HPV negative patients, 97% were Stage IV (AJCC 8th ed.). 77% of all patients received reduced CRT. Median follow-up was 26.7 months. High NLRs after neoadjuvant nivolumab/chemotherapy were associated with worse OS and PFS (p=0.006 and p=0.03, respectively), while baseline high NLRs demonstrated a non-significant trend toward worse OS and PFS (p=0.16 and p=0.10, respectively). In multivariate analysis controlling for tobacco use, ECOG, stage/HPV status, treatment stratification, and PD-L1 CPS, high NLRs after neoadjuvant nivolumab/chemotherapy remained independently associated with worse OS (HR: 5.58, 95% CI: 1.51-20.56, p=0.01) and PFS (HR: 3.09, 95% CI: 1.10-8.67, p=0.03). During follow-up, NLRs were significantly lower in patients receiving reduced CRT compared to those receiving standard CRT at all time points after treatment (p<0.05). Conclusion High NLRs after neoadjuvant immuno-chemotherapy associated with worse survival in locoregionally advanced HNSCC patients. Reduced CRT led to more favorable NLRs which may enhance anti-tumor immunity after neoadjuvant immunotherapy. Further work characterizing dynamic changes in immune phenotype with neoadjuvant HNSCC immunotherapy is warranted.

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib

Neutrophil-lymphocyte Ratio As a Prognostic Factor for Stereotactic Body Radiotherapy Treatment of Metastatic Liver Tumors.

The Prognostic Impact of Neutrophil to Lymphocyte Ratio in Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors.

Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study

Pretreatment Neutrophil to Lymphocyte Ratio is Associated with Response to Therapy and Prognosis of Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy

Neutrophil to Lymphocyte Ratio As a Prognostic Indicator for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study.

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy

Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis

Neutrophil–to–lymphocyte Ratio and Use of Antibiotics Associated with Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer

[Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].

Prognostic Value of Neutrophil–Lymphocyte Ratio, Platelet–Lymphocyte Ratio, and Combined Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio in Stage IV Advanced Gastric Cancer

Neutrophil-to-Lymphocyte Ratio Kinetics and Survival with Neoadjuvant Immuno-chemotherapy and Response-Stratified Chemoradiation in Locoregionally Advanced Head and Neck Cancer

Elevated Neutrophil-to-Lymphocyte Ratio is Associated with Poor Outcomes for Melanoma Patients Treated with PD-1 Inhibitor or Chemotherapy in a Chinese Population.

NLR As a Prognostic Factor in Solid Tumors and in a Transplantable Solid Tumor Mouse Model

High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy

Utility of neutrophil-to-lymphocyte ratio as an indicator of tumor immune status in non-small cell lung cancer

Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation

Prognostic Role of Pretreatment Neutrophil-to-lymphocyte Ratio in Non-Small Cell Lung Cancer Patients Treated with Systemic Therapy: a Meta-Analysis.